

Supplementary Table 1. Clinical characteristics according to the use of DPP-4i in Korean COVID-19 patients with diabetes based on the data from the National Health Insurance Review and Assessment Service of Korea

Characteristic	No DPP-4i user (n=569)	DPP-4i user (n=263)	P value
Age, yr	60.99±16.90	63.69±12.19	<0.0001
<40	65 (11.42)	4 (1.52)	
40 to <50	74 (13.01)	29 (11.03)	
50 to <60	114 (20.04)	61 (23.19)	
60 to <70	125 (21.97)	90 (34.22)	
70 to <80	112 (19.68)	55 (20.91)	
≥80	79 (13.88)	24 (9.13)	
Male sex	296 (52.02)	149 (56.65)	0.2129
Hypertension	371 (65.20)	197 (74.90)	0.0052
Dyslipidemia	483 (84.89)	247 (93.92)	0.0002
Cardiovascular disease	159 (27.94)	68 (25.86)	0.5295
Cerebrovascular disease	64 (11.25)	41 (15.59)	0.0795
Chronic kidney disease	104 (18.28)	58 (22.05)	0.2010
Asthma	166 (29.17)	73 (27.76)	0.6744
COPD	51 (8.96)	21 (7.98)	0.6407
Cancer	136 (23.90)	48 (18.25)	0.0679
Medication			
Metformin	86 (15.11)	183 (69.58)	<0.0001
Sulfonylurea	30 (5.27)	100 (38.02)	<0.0001
Meglitinide	5 (0.88)	2 (0.76)	0.8621
TZD	8 (1.41)	33 (12.55)	<0.0001
DPP-4i	0	263 (100.00)	<0.0001
SGLT2i	18 (3.16)	1 (0.38)	0.0125
AGI	6 (1.05)	1 (0.38)	0.3222
Insulin	1 (0.18)	1 (0.38)	0.5755
RAS blockade	197 (34.62)	130 (49.43)	<0.0001
ACEi	18 (3.16)	6 (2.28)	0.4797
ARB	182 (31.99)	124 (47.15)	<0.0001
Beta blocker	92 (16.17)	46 (17.49)	0.6337
Diuretics	65 (11.42)	46 (17.49)	0.0167
CCB	171 (30.05)	88 (33.46)	0.3237
Statin	207 (36.38)	159 (60.46)	<0.0001
Fibrate	15 (2.64)	17 (6.46)	0.0076

Values are presented as mean ± standard deviation or number (%).

DPP-4i, dipeptidyl peptidase-4 inhibitor; COVID-19, coronavirus disease 2019; COPD indicates chronic obstructive pulmonary disease; TZD, thiazolidinedione; SGLT2i, sodium glucose cotransporter 2 inhibitor; AGI, alpha glucosidase inhibitor; RAS, renin-angiotensin system; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker.